VEL-101 for Kidney Transplant
(RENGEVITY-201 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This study will evaluate the safety and efficacy of VEL-101 compared with tacrolimus in patients undergoing kidney transplantation.
Are You a Good Fit for This Trial?
This trial is for adults (18+) getting a kidney transplant from either a deceased or certain living donors. Participants must be able to follow study procedures, use effective birth control if needed, and have up-to-date vaccinations. People with recent failed transplants due to rejection or recurrent disease in the first year can't join.Inclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Tacrolimus
- VEL-101
Trial Overview
The study compares VEL-101, a new medication, against tacrolimus (a standard anti-rejection drug) to see which better prevents organ rejection after kidney transplantation. Participants are randomly assigned to one of the two treatments.
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
Active Control
VEL-101 Low Dose
VEL-101 High Dose
Tacrolimus
Find a Clinic Near You
Who Is Running the Clinical Trial?
Veloxis Pharmaceuticals
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.